Editor’s highlights from the Journal of Comparative Effectiveness Research – June 2024
In this monthly column, I share some of my Editor’s picks from the June issue of the Journal of Comparative Effectiveness Research (JCER), partner journal of The Evidence Base.
Welcome to my monthly Editor’s highlights from the Journal of Comparative Effectiveness Research (JCER), with my picks from the June issue (Volume 13, Issue 6). This month’s content includes an editorial on the implications of the EU Joint Clinical Assessment (JCA) on patients with rare diseases, along with research examining the economic impacts of the use of polymer-based drug-eluting stents in femoropopliteal artery disease, and sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure.
EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?
The EU HTA JCA is a collaborative initiative aimed at harmonizing the evaluation of clinical evidence for health technologies across the EU and is due to take effect in 2025. In their Editorial, Ramagopalan et al. (Lane Clark & Peacock LLP, UK) discuss its potential impact in rare diseases, arguing that failure to consider real-world evidence in the JCA guidance on indirect comparisons may potentially increase inequity for rare disease patients.
Polymer-based drug-eluting stent treatment extends the time to reintervention for patients with symptomatic femoropopliteal artery disease: clinical evidence and potential economic value
The IMPERIAL study compared the use of a paclitaxel-eluting polymer-coated stent (Eluvia) with a polymer-free paclitaxel-coated stent (Zilver PTX) in the treatment of femoropopliteal arterial segment. In their Short Report, Gray et al. (Thomas Jefferson University, USA) used long-term follow-up data from the study to investigate whether Eluvia treatment can delay the time to restenosis and the need for another procedure compared with Zilver PTX treatment. Additionally, the analysis explored the potential cost savings by avoiding or delaying these repeat procedures.
Cost–effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure
Heart failure is the cause of approximately 84,000 deaths in the USA annually. In their Research Article, Shafrin et al. (FTI Consulting, USA) analyzed data on sotagliflozin from the SOLOIST-WHF trial (a Phase III, double-blind, randomized, placebo-controlled study) to investigate the cost–effectiveness of sotagliflozin for the treatment of patients hospitalized with heart failure and comorbid diabetes.
You may also be interested in:
Spotlight: Joint Clinical Assessment in Europe
The JCA in Europe is set to harmonize the clinical evaluation of medicines and certain medical devices across EU Member States, with the aim of reducing duplication of work and accelerating patient access. Read selected coverage from The Evidence Base, covering this important and complex topic.
In addition to my Editor’s highlights, you can read the full June issue of JCER here, where all the articles are Open Access and freely available to read. The journal welcomes pre-submission enquiries, so do get in touch if you would be interested in contributing.
